PDS Biotechnology Corp (PDSB)
PDS Biotechnology develops immunotherapies that aim to treat cancer and to prevent infectious diseases. It last closed at $0.89 on Nov 17, down 3.28% on the day. The average 12-month price target from 2 analysts is $4.50 (+403.5% from the last close), with a high of $5.00 and a low of $4.00.
Key Stats
Last 12 monthsNot reported for this period.
From PDSB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on PDSB in the past 90 days. The average target is $4.50, with a high of $5.00 and a low of $4.00, compared with the last close of $0.89.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | B. Riley Securities | Reiterated | Buy | $4 |
| Sep 8 | HC Wainwright & Co. | Target lowered | Buy | $7 → $5 |
| Aug 26 | HC Wainwright & Co. | Reiterated | Buy | $7 |
| Aug 13 | HC Wainwright & Co. | Maintained | Buy | $7 |
Technical Analysis
The stock is 32% below its 20 day and 13% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Jun 16) at $0.87, and the nearest resistance the Pivot at $0.92.
| RSI (14) | 41.52 | Middle of its range | Neutral |
| MACD | -0.04 | Below its signal line | Bearish |
| Stochastic | 14.4 | Near the bottom of its range | Oversold |
| ADX (14) | 29.1 | Trending down | |
| Williams %R | -86.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -102.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −36.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.17 | Typical daily range, 18.8% of price |
| RSI (14) | 50.34 | Middle of its range | Neutral |
| MACD | 0.07 | Above its signal line | Bullish |
| Stochastic | 50.4 | Middle of its range | Neutral |
| ADX (14) | 30.4 | Trending up | |
| Williams %R | -56.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 27.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +203.1% | Change over 10 sessions | Bullish |
| ATR (14) | $0.33 | Typical daily range, 37.0% of price |
What happened before
See how PDSB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PDSB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in PDSB in the last 90 days.
PDSB Institutional Ownership
Full report →- ▲32 buying vs 18 selling
- ▲Held by funds +3.1 pts
- ▲Funds holding +10
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 62 | 52 | +19.2% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 10.5% | 7.3% | +3.1 pts |
| New / increased | 18 / 14 | 14 / 13 | +18.5% |
| Reduced / sold out | 12 / 6 | 7 / 4 | +63.6% |
| Put/call ratio | 0.29 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PDSB is in one of them and how their past PDSB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PDSB in an article yet. Here's the latest on the wider market.
About PDS Biotechnology
PDS Biotechnology is a clinical stage immunotherapy company based in Princeton, New Jersey. It is developing cancer treatments built on its Versamune platform, including a combination with an interleukin 12 antibody drug conjugate, and an Infectimune T cell activator for preventive vaccines against infectious agents. The Versamune platform is a lipid nanoparticle designed to stimulate the immune system's killer and helper T cells. Its investigational products are aimed at patients with cancer and at preventive vaccines for infectious diseases.
- Headquarters
- Princeton, NJ

